

Models of intrahepatic cholangiocarcinoma: novel tools and therapeutic applications

Margaret A Hill^{1,2,*}William B Alexander^{1,2,*}Aram F Hezel^{1,2}

¹Department of Biomedical Genetics, ²Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA

*These authors contributed equally to this work

Abstract: Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy, and a number of recent studies have identified an increasing trend in incidence and mortality. As an aggressive disease characterized by early metastasis, surgical resection is not an option for most patients, and chemotherapy has limited benefit. Thus, the prognosis is extremely poor, warranting the development of novel models to improve detection and treatment strategies for this lethal cancer. In this regard, significant technological advancements have provided key tools to model and study iCCA. Furthermore, these technologies are addressing the need for models that can readily be adapted to address different genetic contexts, an important consideration for genetically diverse cancers such as iCCA. In this review, we outline these various available tools, discussing specifically how they have been employed to study iCCA while highlighting important therapeutic implications. Finally, we discuss novel strategies utilizing patient-derived tumor tissue which have promising translational applications.

Keywords: cholangiocarcinoma, biliary cancer, models, cell of origin, Cre-Lox, sleeping beauty

Introduction

Intrahepatic cholangiocarcinoma (iCCA) is an extremely lethal cancer with limited therapeutic options; therefore, novel approaches to early detection and treatment are desperately needed.¹ Key to this is the development of models that accurately recapitulate critical aspects of human iCCA to both better understand the underlying biology of the disease and provide systems in which new therapeutic strategies can be explored. Furthermore, iCCA is a genetically diverse cancer, and designing flexible models that can readily be adapted to reflect this genetic complexity is of paramount importance.

In this review, we discuss the various strategies that have been employed to model iCCA. Throughout, we highlight important biological insights made possible by the specific models and also discuss related therapeutic implications. In deciding how to best utilize these models and how to approach the development of new models, there are a number of important considerations, which are outlined in Box 1. Balancing these often requires a combination of complementary approaches, which is evident in the crossover of technologies in some of the sections of this review. To date, Cre-Lox-based genetically engineered mouse models (GEMMs) have proven to be an invaluable resource for studying iCCA, and therefore, we devote significant space to describing their utility and contributions. We further discuss novel approaches that have been applied to modeling iCCA using non-germline-based technologies. Finally, we focus on recent developments that rely on patient-derived tumor tissue, patient-derived tumor

Correspondence: Aram F Hezel
Department of Medicine, Hematology/
Oncology, Wilmot Cancer Institute,
University of Rochester School of
Medicine, 300 Elmwood Avenue,
Rochester, NY 14642, USA
Tel +1 585 273 4150
Fax +1 585 276 0337
Email Aram_Hezel@URMC.Rochester.
edu

xenografts (PDTXs), and organoids, which have significant potential for translational applications.

Chemical and surgical models

Historically, rodent models of liver carcinogenesis have heavily relied upon administering exogenous toxic agents that induce injury and/or carcinogenesis, in part due to the liver conveniently being the central organ for toxin metabolism. In addition to being extremely practical immunocompetent *in vivo* models, these agents can also recapitulate features of premalignant and malignant disease, which may not accompany other models that depend strictly on genetic perturbations, such as ductular reactions or fibrosis. A wide array of liver injury agents exist.^{2,3} Those that have been utilized to study cholangiocarcinoma (CCA) in particular are listed in Table 1. Briefly, the nitrosamines, diethylnitrosamine and dimethylnitrosamine, and thioacetamide (TAA) have both been used as carcinogens, as they can reliably lead to cancer without additional agents or engineered mutations.^{13,16–18} It is important to note that hepatocellular carcinoma (HCC) may be the dominant tumor type arising in carcinogenic

models. Most often, an additional oncogenic event, such as liver fluke infection or biliary-specific deletion of a tumor suppressor, is needed to promote iCCA development.^{17,18}

Although such extreme carcinogenic injury is not frequently recognized epidemiologically among human iCCA, tumors arising in this context are likely more genetically diverse and, therefore, can be useful for study when the genetic context is of minimal importance. Carbon tetrachloride (CCl₄), a less severe agent, induces liver fibrosis and cirrhosis, relevant features of human CCA, and, in a *Tp53*-null setting, promotes iCCA development.¹⁹ Finally, bile duct ligation (BDL) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) are used to induce cholestatic injury and ductular reactions, a common feature of liver fluke infections and early iCCA development.^{13,20–22} When deciding which chemical agents to use, one must consider both the context in which the toxin is to be used and which aspects of injury are most important for the study. For example, if a defined genetic context is desired, a carcinogenic injury model that has an unpredictable genetic progression should be discouraged. In other studies, groups may want to induce a specific feature of liver injury

Box 1 Considerations for the development and utilization of iCCA models

Genetics:	Are specific genetic alterations relevant to the scientific question?
Biologic context:	Is an <i>in vivo</i> environment necessary? Should the host be immune competent? Is it important to model the pathologic progression of the disease?
Pathogenic context:	Is the pathogenic setting in which the tumor developed (eg, liver fluke infection, fibrosis) relevant?
Cell of origin:	What cell compartment, hepatocytes and/or biliary epithelial cells (BECs), should be targeted (eg, when targeting mutations using Cre-Lox technology)?
Practicality:	Considering that the available modeling systems widely vary in the resources they require (ie, cost and time), how does one optimally utilize the different systems to address the scientific question?

Abbreviation: iCCA, intrahepatic cholangiocarcinoma.

Table 1 Summary of injury and carcinogen models

Agent	Characteristics	Mutations	Animal	Reference
TAA	Carcinogen, fibrosis	<i>Krt19-Cre^{ERT}; Rosa26^{LSL-YFP}; Tp53^{flf}</i>	Mouse	17, 48, 49
		<i>Alb-Cre^{ERT}; Rosa26^{LSL-LacZ}</i>	Mouse	16
		WT	Rat	5, 49
DEN/DMN	Carcinogen, fibrosis	<i>Alb-Cre^{ERT}; Hnf4a^{flf}</i>	Mouse	20
		<i>Phd2^{+/-}</i>	Mouse	4
		WT with BDL	Mouse	6
		WT with <i>O. viverrini</i> infection	Hamster	8–12, 18
		WT with <i>C. sinensis</i> infection	Hamster	13
CCl ₄	Fibrosis	<i>Tp53^{+/-}</i> and <i>Tp53^{flf}</i>	Mouse	19
DDC	Cholestatic injury, ductular reaction, biliary fibrosis	<i>Prom1-Cre^{ERT}; Tgfb2^{flf}; Pten^{flf}</i>	Mouse	14
		<i>Prom1-Cre^{ERT}; Kras^{LSL-G12D}; Tp53^{flf} and Tp53^{+/+}</i>	Mouse	22
		<i>Prom1-Cre^{ERT}; Pten^{flf}; Tp53^{flf}</i>	Mouse	22
		<i>Prom1-Cre^{ERT}; Pten^{flf}; Cdkn2a^{flf}</i>	Mouse	22
BDL	Cholestatic injury, ductular reaction, biliary fibrosis	WT with DEN	Mouse	7
		SB-mediated AKT and YAP overexpression	Mouse	15, 59, 61

Abbreviations: BDL, bile duct ligation; CCl₄, carbon tetrachloride; *C. sinensis*, *Clonorchis sinensis*; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DEN, diethylnitrosamine; DMN, dimethylnitrosamine; *O. viverrini*, *Opisthorchis viverrini*; SB, sleeping beauty; TAA, thioacetamide; WT, wild type.

for which a chemical or surgical model is best suited. For example, in an extended experiment assessing the impact of ductular reactions on iCCA development, a flexible dietary model like DDC may be preferable to a surgical model BDL, which is more suitable for short-term experiments. These various models continue to play a key role in the study of liver-related malignancies, and in particular, integrating them with other advanced genetic tools, as addressed in the following sections, has shed much light on the development and biology of iCCA.

Cre-Lox-based models

Conditional GEMMs that utilize Cre-Lox technology have been one of the most powerful tools available to understand the development and progression of cancer.²³ In this review, we outline how this technology has been utilized to study the liver and liver-related malignancies and highlight a number of important considerations (Table 2). Cre-Lox technology is a conditional system that uses a Cre-recombinase allele to excise DNA between two *LoxP* sites oriented in the same direction. Depending on the location of *LoxP* sites, it can be used to both inactivate and activate genes. Engineered alleles for oncogenic *Kras* and *Tp53* provide examples and have been used cooperatively in models of iCCA. The *Trp53*^{fllox} allele has *LoxP* sites engineered in introns 1 and 10, leading to deletion of exons 2–10 upon Cre-mediated recombination, thereby inactivating *Tp53*.³⁶ Alternatively, an oncogenic allele can be rendered conditional by inserting a *Stop* codon flanked by a *LoxP* site upstream. The *Kras*^{LSL-G12D} allele is composed of the constitutively active *Kras* mutant which in the absence of Cre-recombinase is not transcribed due to the upstream *Lox-Stop-Lox* (*LSL*) element; however, upon Cre-mediated recombination, the *Stop* codon is excised and the oncogenic allele is expressed.³⁷

Tissue specificity and temporal control can be achieved with this system by placing the *Cre* under the control of a cell- or tissue-specific promoter, thereby generating *LoxP* site recombination exclusively in that lineage (Figure 1). Alternatively, viruses that have tissue-specific tropisms can be used to deliver Cre-recombinase. Adeno-associated virus 8 (AAV8) is a notable example that has a hepatocyte-specific tropism and is therefore frequently used to target hepatocytes while excluding biliary epithelial cells (BECs).³⁸ In addition, the *Cre*^{ERT} system, a fusion of *Cre* and the tamoxifen-inducible domain of the estrogen receptor (ER), enables spatiotemporal control, which has been crucial for the generation of BEC-specific *Cre* alleles and manipulating genes in the

adult mouse that would otherwise be necessary for normal development.^{21,39}

Further specificity can be achieved with tetracycline (Tet) expression systems that come in two forms, Tet-on or Tet-off, depending on whether promoter function is enabled or disabled by exogenous Tet administration. Both systems require the addition of either a *tTA* or *rtTA* allele, respectively. A significant advantage to using a Tet expression system is that induction via Tet is reversible (unlike *Cre*^{ERT}), and combining this system with Cre-Lox technology through addition of an *LSL* between the promoter and start codon of the Tet-controlled transactivator can enable tissue specificity as well. One such example is the *Tet-IDH2*^{LSL-R140Q} allele that when combined with *Rosa26*^{LSL-rtTA} and *Alb-Cre* restricts Tet-inducible expression of mutant *IDH1* to the liver.²⁰ Another useful tool that can be combined with Cre-Lox is the flippase (FLP)-recombinase target (FRT) system, which functions analogously: an FLP recombinase excises DNA between two *FRT* sequences. It has been employed in the liver in combination with Cre-Lox to enable highly specific labeling of SOX9-positive hepatocytes, a unique compartment with potential to regenerate hepatocytes and BECs following injury.⁴⁰ Thus, these systems, which allow for broad or specific manipulation of organs and cell types, are essential tools for modeling the various aspects of the human disease in mice.

There are several important considerations that investigators should bear in mind in applying these mutagenesis strategies. When using a *Cre* that is active in the liver progenitor population, such as the *Alb-Cre* allele, both liver cell types will be affected, limiting conclusions that can be drawn about the cell of origin. In addition, when using *Cre*^{ERT} systems, the timing of tamoxifen administration may be critical. *Alb-Cre*^{ERT}, for example, can label a small proportion of BECs, potentially confounding lineage tracing and cell of origin experiments.^{40,41} Also, all of the listed BEC-specific *Cre* drivers label epithelial cells across multiple organs including the lung, pancreas, and colon; in the absence of additional liver-specific oncogenic challenges, these experimental animals often develop tumors outside of the liver.⁴¹ Nevertheless, significant advancements have been made in iCCA biology using the Cre-Lox system. In this review, we discuss more specifically how Cre-Lox-based GEMMs have advanced our understanding regarding three related topics: the cell of origin, the function of common mutations, and processes important for tumor development and maintenance.

Table 2 Summary of iCCA Cre-Lox GEMMs

Cre driver	Mutations	Tumor spectrum	Key finding	Reference
Cre activity: hepatoblasts				
Alb-Cre	<i>Kras</i> ^{LSL-G12D} ; <i>Tp53</i> ^{fl/fl} and <i>Tp53</i> ^{fl/+}	Mostly iCCA, some mixed, rare HCC in <i>Tp53</i> ^{fl/fl}	Tumors have high levels of basal autophagy	47
	<i>Kras</i> ^{LSL-G12D} ; <i>IDH2</i> ^{R172K}	Exclusive iCCA	<i>IDH2</i> mutation promotes biliary differentiation	20
	<i>Kras</i> ^{LSL-G12D} ; <i>Cdh1</i> ^{fl/fl}	Mostly HCC, some mixed, some iCCA	<i>Cdh1</i> suppresses EMT and liver tumorigenesis	4
	<i>Kras</i> ^{LSL-G12D} ; <i>Pten</i> ^{fl/fl} and <i>Pten</i> ^{fl/+}	Exclusive iCCA in <i>Pten</i> ^{fl/fl}	<i>Pten</i> status may determine tumor spectrum	41
	<i>Pten</i> ^{fl/fl}	Mostly mixed, some iCCA	miR-21 is important for tumor development and growth	24, 25
	<i>Pten</i> ^{fl/fl} ; <i>Tgfb2</i> ^{fl/fl}	Mixed and iCCA	<i>Tgfb2</i> deletion shifts tumor phenotype from HCC to iCCA	14, 26
	<i>Pten</i> ^{fl/fl} ; <i>Smad4</i> ^{fl/fl}	Exclusive iCCA	Deletion of <i>Pten</i> and <i>Smad4</i> cooperate to induce iCCA	27
	<i>Pten</i> ^{fl/fl} ; <i>Grp78</i> ^{fl/fl}	HCC, mixed, iCCA – proportions unclear	<i>Grp78</i> mediates liver cancer progression induced by <i>Pten</i> loss	28
	<i>Pten</i> ^{fl/fl} ; <i>Grp94</i> ^{fl/fl}	HCC, mixed, iCCA – proportions unclear	Double KO has accelerated tumorigenesis and ERK activation	29
	<i>Rosa26</i> ^{LSL-NICD}	Exclusive iCCA	<i>Notch</i> activation can drive iCCA	30
	<i>Rosa26</i> ^{LSL-NICD} ; <i>Tp53</i> ^{fl/fl}	Exclusive iCCA	<i>Notch</i> activation and <i>Tp53</i> deletion cooperate to induce iCCA	32
	<i>Mob1a</i> ^{fl/fl} ; <i>Mob1b</i> ^{-/-}	Mostly mixed, some iCCA, some HCC	Inactivation of Hippo signaling can promote iCCA	31
	<i>Tp53</i> ^{fl/fl}	HCC, mixed, iCCA – proportions unclear	Deletion of <i>Tgfb2</i> decreases tumor formation and growth	33
Alfp-Cre	<i>Tp53</i> ^{fl/fl}	HCC, mixed, iCCA – proportions unclear	Tumors with <i>Tp53</i> deleted express stem cell marker Nestin	46
Cre activity: hepatocytes				
Alb-Cre ^{ERT2}	<i>Rosa26</i> ^{LSL-LacZ} or <i>Rosa26</i> ^{LSL-YFP} + TAA	Exclusive iCCA	Mutated hepatocytes can give rise to iCCA	16, 34
	<i>Hnf4a</i> ^{fl/fl} + DEN/DMN	Exclusive iCCA	<i>Hnf4a</i> suppresses iCCA development	20
	<i>Kras</i> ^{LSL-G12D} ; <i>Pten</i> ^{fl/fl}	iCCA with early Tam; HCC with late Tam	Tumors arise from BECs with early Tam administration	41
AAV8-TBG-Cre	<i>Pten</i> ^{fl/fl} ; <i>Tgfb2</i> ^{fl/fl}	Mostly iCCA, rarely mixed, and HCC	Mutated hepatocytes can give rise to iCCA	14
Cre activity: BECs				
Krt19-Cre ^{ERT}	<i>Rosa26</i> ^{LSL-YFP} ; <i>Tp53</i> ^{fl/fl} + TAA	Exclusive iCCA	BEC-specific <i>Tp53</i> deletion can promote iCCA	17, 48, 49
	<i>Kras</i> ^{LSL-G12D} ; <i>Pten</i> ^{fl/fl}	Exclusive iCCA	<i>Kras</i> and <i>Pten</i> mutations in BECs give rise to iCCA	41
	<i>Pten</i> ^{fl/fl} ; <i>Tgfb2</i> ^{fl/fl} + DDC	Exclusive iCCA	Mice develop iCCA	14
Ah-Cre ^{ERT}	<i>Pten</i> ^{fl/fl} ; <i>Kras</i> ^{LSL-V12D}	Exclusive iCCA	<i>Pten</i> and <i>Kras</i> cooperate to form iCCA	35
Prom1-Cre ^{ERT2}	<i>Pten</i> ^{fl/fl} ; <i>Tgfb2</i> ^{fl/fl} + DDC	Exclusive iCCA	Mice develop iCCA	14
	<i>Pten</i> ^{fl/fl} ; <i>Tp53</i> ^{fl/fl} + DDC	HCC, mixed, iCCA – proportions unclear	Liver injury increases liver cancer risk	22
	<i>Pten</i> ^{fl/fl} ; <i>Cdkn2a</i> ^{fl/fl} + DDC	HCC, mixed, iCCA – proportions unclear	Liver injury increases liver cancer risk	22
	<i>Kras</i> ^{LSL-G12D} ; <i>Tp53</i> ^{fl/fl} and <i>Tp53</i> ^{+/-} + DDC	HCC, mixed, iCCA – proportions unclear	Liver injury increases liver cancer risk	22

Abbreviations: AAV8, Adeno-associated virus 8; BECs, biliary epithelial cells; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; EMT, epithelial-mesenchymal transition; GEMMs, genetically engineered mouse models; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; NICD, Notch I intracellular domain; Tam, tamoxifen.

Cell of origin

Although the BEC has historically been the assumed cell of origin for iCCA, several observations suggest a more complex origin, including the existence of mixed HCC–iCCA tumors,

an association with chronic hepatocellular injury, and the recently recognized capacity for hepatocytes to transdifferentiate into BECs.^{1,42} To test the possibility that hepatocytes can be the cell of origin for iCCA, one experiment lineage




Figure 1 Schematic of Cre driver activity within the liver.

Note: *Specificity depends on when tamoxifen is administered.

Abbreviation: BEC, biliary epithelial cell.

traced the hepatocyte compartment with an AAV8-Ttr-Cre and a *Rosa26^{LSL-YFP}* reporter.⁴³ Using sleeping beauty (SB) transposase (to be discussed) to express *AKT* and a constitutively active Notch1 intracellular domain (NICD) in the liver, iCCAs developed that expressed the YFP marker, indicating a hepatocyte origin. In another experiment, hepatocytes and BECs were lineage traced using the *Alb-Cre^{ERT}* and *Krt19-Cre^{ERT}*, respectively, with the *Rosa26^{LSL-lacZ}* reporter.¹⁶ Following iCCA induction via the carcinogen TAA, iCCAs with β -gal activity were present only in the *Alb-Cre^{ERT}* cohort, similarly illustrating hepatocytes as a possible cell of origin. On the other hand, when *Krt19-Cre^{ERT}* is used to delete *Tp53* and label BECs, thereby predisposing BECs to oncogenesis, it was demonstrated that TAA administration induces iCCA that is of biliary origin.¹⁷ Finally, in another key experiment demonstrating BECs as a cell of origin, induction of *Kras* and *Pten* mutations in BECs via *Krt19-Cre^{ERT}* promoted iCCA development.⁴¹ Notably, mice in the latter experiment also exhibited significant extrahepatic tumor burden, illustrating a critical limitation of alleles such as *Krt19-Cre^{ERT}* and *Hnf1b-Cre^{ERT}* that are active in extrahepatic epithelial compartments as well. Altogether, the current evidence supports the notion that both hepatocytes and BECs can be a cell of origin in iCCA depending on the context (Figure 2). Understanding distinguishing biological features of BEC-derived and hepatocyte-derived iCCAs may prove to be relevant in the development of future therapeutic strategies.

Function of common mutations

In recent large-scale sequencing studies, the genetic landscape of iCCA has come into view. In non-liver fluke-related iCCA, the most common mutations are in *IDH1/2* (22%), *BAP1* (22%), *TP53* (7%), *KRAS* (7%), and *ARID1A* (7%). Liver fluke-related iCCA, on the other hand, is distinguished by mutations in *TP53* (45%), *KRAS* (19%), *SMAD4* (16%), *ARID1A* (12%), and *KMT2C* (11%).^{44,45} Cre-Lox-based




Figure 2 Current model of the cells of origin in primary liver cancers.

Abbreviations: BEC, biliary epithelial cell; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma.

GEMMs have proven useful in discerning the functions of some of these mutations in iCCA. To explore the function of *IDH1/2* mutations in iCCA, *Alb-Cre* was utilized to enable Tet-inducible expression of oncogenic *IDH1/2* mutations in the liver, demonstrating that mutant *IDH1/2* function to inhibit hepatocyte differentiation via epigenetic silencing of the major regulator of hepatocyte identity, *Hnf4a*, a key driver of hepatocyte differentiation.²⁰ In a similar theme of mutations that impact cellular differentiation, *Tp53* deletion in an *Alfp-Cre*-driven model leads to poorly differentiated liver tumors that have high expression of the stem cell marker Nestin and can be further directed toward a hepatocellular or biliary fate with additional lineage-specific mutations. Thus, *Tp53* is an important suppressor of liver cell plasticity.⁴⁶ Finally, *Alb-Cre*-driven *Kras^{G12D}* expression and *Tp53* deletion was shown to promote development of iCCAs that depend on autophagy, an important downstream process in many *Kras*-driven tumors.⁴⁷ Despite significant progress in the past decade, much remains to be explored regarding the roles of these and many other oncogenic mutations found in iCCA.

Critical processes for tumor development and maintenance

Cre-Lox-based GEMMs are an essential tool to study and model the development of cancer in ways that accurately recapitulate the natural disease progression and tumor microenvironment. In addition to studying the importance of downstream pathways using genetic strategies, these models provide the opportunity to test potential therapeutic interventions in a relevant in vivo setting. In this regard, one group showed that iCCA in the *Krt19-Cre^{ERT};Tp53^{fl/fl}* TAA model, a rat TAA model, and xenograft models are all sensitive to

both macrophage-inhibiting therapies and Wnt-inhibiting therapies.⁴⁸ The same research group again employed the *Krt19-Cre^{ERT};Tp53^{fl}* TAA and rat TAA models to demonstrate that the Notch pathway may be an additional therapeutic target.⁴⁹ One strategy put the mouse model on a Notch3 null genetic background, finding that there is comparably minimal tumor development in this setting. Furthermore, pharmacologic inhibition of Notch signaling in the rat model similarly reduced tumor formation. These results suggest that further development of strategies to target these processes may be worthwhile. Finally, although not illustrated in the aforementioned examples, another clear advantage to GEMMs is the presence of an intact immune system. This important feature has been exploited in GEMMs of other malignancies such as pancreatic cancer to test T-cell-directed immunotherapies such as promising anti-PD-1/PD-L1 therapies.⁵⁰

Novel Cre-Lox tools

Despite the many advantages offered by the Cre-Lox-based GEMMs described earlier, the newly discovered breadth of mutations in this disease and the need to rapidly evaluate different combinations of mutations warrant the development of more efficient modeling strategies. To address this need, there have been a number of recent efforts to generate non-germline Cre-Lox models. One approach involves the culture of embryonic hepatoblasts from *Alb-Cre Kras^{LSL-G12D} Tp53^{LSL-R172H}* mice, which can then be orthotopically transplanted into a syngeneic host to generate iCCA within several months.⁵¹ These mutant hepatoblasts can be further manipulated to validate other oncogenic drivers and evaluate their potential as a therapeutic target. For example, to determine the impact of a newly identified fusion gene, *FIG-ROS1*, on iCCA growth, a Tet-inducible *FIG-ROS1* gene was introduced into the hepatoblast-allograft model, dramatically accelerating tumor development. Furthermore, turning off *FIG-ROS1* expression via doxycycline withdrawal resulted in dramatically slower tumor progression. A similar strategy could express shRNAs to determine the impact of knocking down putative tumor suppressors or putative tumor-promoting genes. In addition to the improved flexibility and ease of generation in comparison to traditional GEMMs, this approach has the additional advantage of not generating mutations throughout the entire organ, thus maintaining an environment that consists of cells not genetically predisposed to cancer, more akin to human tumors.

Another promising strategy has been developed to study pancreatic cancer and represents a system that could be adapted to study liver malignancies as well.⁵² Embryonic stem

cells (ESCs) were established that contain a pancreas-specific driver (*Pdx-Cre* or *p48-Cre*) and the *Kras^{LSL-G12D}* allele. In addition to these features, the cells harbor a “recombinase-mediated cassette exchange” strategy for rapid exchange of Tet-inducible shRNA- or cDNA-expressing constructs accompanied by a fluorescent reporter and a Cre-dependent Tet-transactivator accompanied by a different fluorescent reporter. The ESCs can be manipulated in vitro to introduce the shRNA/cDNAs of interest and subsequently used to generate chimeric mice for study. This flexible technology enables a variety of questions to be asked, illustrated by the following examples. First, by introducing a doxycycline-inducible shRNA-targeting *Pten*, they demonstrated that knockdown of a tumor suppressor can accelerate *Kras*-induced tumorigenesis. Furthermore, doxycycline withdrawal, resulting in reexpression of *Pten*, causes a dramatic decrease in tumor burden and an increase in survival. To determine the role of *Myc* in pancreatic tumor development, they employed tandem shRNA technology to introduce an shRNA targeting *Tp53*, which similarly accelerates tumorigenesis, and an shRNA targeting either *Myc* or a control shRNA. Compared to the control shRNA, tumor development in the *Myc* knockdown cohort was significantly impaired, confirming a role for *Myc* in promoting tumor development.

Thus, these technologies maintain many of the advantages of traditional germline GEMMs: the ability to make temporal- and tissue-specific genetic perturbations in an immune-competent environment, thereby generating cancers that closely follow the histopathologic progression of human disease. However, they offer flexible strategies to bypass the extensive breeding required to address similar questions with germline GEMMs.

SB models

Given the limitations associated with Cre-Lox GEMMs, a number of alternative approaches have been developed. The mouse liver is readily accessible via hydrodynamic tail vein injection (HTVI) for delivery of plasmids, but due to the transient nature of traditional expression plasmids, sustained expression of transcripts for oncogenic studies is a challenge.⁵³ Thus, the SB transposon system has found particular relevance in enabling stable integration of transgenes in the mouse liver (Table 3). The SB transposon is a cut and paste element, which was created based on the inactive Tc1/*mariner* superfamily of transposons in fish. The transposase recognizes inverted repeat (IR) sequences that flank a DNA sequence, excise that DNA, and insert it at thymine and adenine sites elsewhere in the

Table 3 Summary of iCCA SB models

Model	Tumor spectrum	Key finding	Reference
AKT; NRAS	Mostly HCC, some mixed, some iCCA	Coactivation of Akt and Ras signaling induces liver tumors	56
		Notch signaling is critical for liver tumor development	57
		Bmi1 is critical for liver tumor development	58
AKT; NICD	Exclusive iCCA	iCCA can originate from AKT/NICD-mutant hepatocytes	43
AKT; Jag1	Exclusive iCCA	AKT/Jag1 cooperate to form iCCA	55
Akt; YAP + IL-33 and BDL	Exclusive iCCA	IL-6 promotes tumorigenesis	15, 59
		Treatment with FGFR inhibitor reduces tumor burden	61
Yap1; PIK3CA	Mostly HCC and mixed, some iCCA	Yap1/PIK3CA cooperate to induce liver tumors	60
YAP; shTp53	Mixed – undifferentiated tumors	Nestin is required for tumorigenesis	46
YAP; shTp53 + shAPC or NICD	iCCA if NICD, HCC if shAPC	Tumor differentiation could be directed	46
NICD; IDH1; shTp53	Exclusive iCCA	All three cooperate to induce iCCA	54

Abbreviations: BDL, bile duct ligation; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; IDH1, IDH1R132C; NICD, Notch1 intracellular domain; PIK3CA, PIK3CAH1047R; YAP, YAPSI27A; SB, sleeping beauty.

genome. The endogenous SB transposon is a single element, where the SB transposase gene is flanked by IR/direct repeat (DR) sequences. In order to use this system experimentally, the SB transposase and IR/DR sequences have been separated where the IR/DR sequences flank the gene of interest and are often introduced as unique vectors.

To drive iCCA development, a number of studies have employed an activated form of Notch signaling in combination with various other perturbations including activation of PI3K signaling, activation of Yap signaling, mutant IDH1 expression, and *TP53* knockdown.^{43,46,54,55} Notch-independent models have also been generated, including coactivation of Yap/PI3K signaling and mutant Kras/PI3K signaling.^{15,46,56–61} While tail vein injection is believed to largely target hepatocytes, targeting the biliary tract specifically was achieved by injecting plasmids directly into the gallbladder following bile-duct ligation, thereby preventing spillover into the gut. It was further demonstrated that *Yap* and *Akt* expression in this setting cooperate to induce iCCA in a small proportion of mice, a phenotype that significantly increased when IL-33 is systemically administered.

SB technology has also been adapted for forward genetic mutagenesis screens to identify genes that are critical in regulating liver cancer development.^{62,63} This is achieved using a Cre-Lox-regulated SB transposase and a T2/onc transposon which can lead to expression of an oncogene or inactivation of a tumor suppressor. In an SB mutagenesis screen using livers predisposed to tumor development via expression of dominant negative *TP53* (*TP53*^{LSL-R270H}), sequencing of the resulting tumors revealed genes that are known HCC drivers such as *Egfr* and *Met*, as well as a number of novel genes not previously implicated in cancer. Another experiment used *Myc* overexpression to predispose the liver to tumorigenesis

and a similar SB mutagenesis strategy to identify *Ncoa2* as a novel tumor suppressor. Currently, these screens in the liver have focused on HCC; thus, similar approaches remain to be employed in a setting that will lead to iCCA.

CRISPR/Cas9 models

Another especially promising gene-editing tool is the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system.⁶⁴ Like SB, CRISPR/Cas9 offers an efficient method to introduce oncogene expression, but it has additional flexibility to inactivate genes such as tumor suppressors and repair genes with point mutations. In brief, the Cas9 nuclease is directed to a target sequence via a single-guide RNA (sgRNA), where double-strand breaks are repaired by error-prone nonhomologous end joining (NHEJ), often resulting in insertion/deletions (indels) that can disrupt a locus through introduction of reading frame shifts. Alternatively, investigators can use homology-directed repair (HDR) to create specific mutations through use of a DNA template to guide homologous recombination (HR).

To date, there are three hallmark studies that illustrate various ways in which CRISPR/Cas9 technology can be applied to the murine liver. One group used HTVI to introduce a single vector containing both Cas9 and sgRNAs to target *Pten* and *TP53*.⁶⁵ Phenocopying the comparable Cre-Lox model, loss of *Pten* alone led to up-regulation of AKT, and loss of both *Pten* and *TP53* resulted in iCCA. Investigators also showed that gain-of-function mutations can be introduced through HDR, paving way for CRISPR/Cas9 modeling of oncogenic mutations commonly used in GEMMs, such as *Kras*^{G12D}. Another group, which also sought to disrupt tumor suppressors, attempted to achieve long-term

in vivo CRISPR/Cas9 activity by combining it with the SB transposon system to incorporate Cas9 and the sgRNAs into the genome.⁶⁶ Although very few tumors had stable integration of the CRISPR/Cas9 vectors, this study established an effective strategy to model mutations in large gene sets in the mouse liver, which is particularly advantageous for verifying tumor-causing mutations (ie, driver versus passenger mutations). Finally, CRISPR/Cas9 was used to repair a disease-causing point mutation in the *Fah* gene, that causes hereditary tyrosinemia type I in mice.⁶⁷ Investigators were able to successfully mend the mutation and also demonstrate that the mice regained weight, signifying alleviation of the disease burden. An interesting therapeutic application related to this is the possibility of repairing point mutations important for tumorigenesis. Currently, however, it should be noted that this strategy corrects mutations in a very small proportion of cells, which may be best suited for instances where the repaired cells have a selective growth advantage. Thus, although promising, much improvement is needed regarding the delivery and repair efficiency of this system for it to be applied therapeutically to reverse cancer causing mutations.

Patient-derived models

The utility of studying human cancer cell lines in the culture dish and as xenografts is well established, and they will continue to be critical in understanding the biology of the disease and in developing therapeutic strategies. In this review, we highlight novel approaches that can offer some advantages over these traditional models.

PDXs

The applications of PDXs have been rapidly expanding, from studying biological processes to predicting the therapeutic response of patient samples.^{68,69} Unlike cell line xenografts where cultured cell lines are injected into immune-deficient mice, PDXs are implanted tumor fragments taken from biopsy, maintaining key features of the tumor lost in two-dimensional (2D) culturing such as stroma, architecture, and heterogeneity. Preserving these qualities has allowed for accurate prediction of therapeutic sensitivities in numerous other cancers.^{70–72} Recently, multiple groups demonstrated successful PDX models of CCA. A *KRAS*-mutant iCCA model was generated and shown to retain many features of the original tumor, including immunoreactivity and miRNA expression.⁷³ Another group showed an *IDH1*-mutant PDX displayed sensitivity to dasatinib, a multi-tyrosine kinase inhibitor shown to have efficacy on *IDH1*-mutant iCCA cells in vitro.⁷⁴ Similarly, two PDX models of iCCA were treated with an FGFR inhibitor,

and the YAP-driven model displayed significantly reduced growth with treatment, supporting the group's in vitro finding of a feed-forward loop between YAP and FGFR signaling.⁶¹ Some key limitations nevertheless exist for PDX models. First, there is substantial variability in the success rate for creating PDXs both among different cancers as well as between laboratories. Relatedly, the tumors that do successfully take in mice likely represent only the highly aggressive tumors. Finally, extensive time is required for the development of PDXs, up to several months for the establishment of the primary graft, which is an especially important factor if being used to predict therapeutic response of a patient's tumor.

Organoids

A growing interest has developed regarding the utility of “organoid” models, a culture system in which cells are grown in a three-dimensional matrix and organize into epithelial-like structures that resemble the tissue of origin.^{75–77} Although liver cancer models remain to be adapted for this system, organoids have shown promise in a related gastrointestinal malignancy, pancreatic cancer. For example, one group fully characterized organoids derived from both normal, premalignant, and malignant pancreatic tissue from murine and human sources, demonstrating that organoids display morphological features and express markers that reflect the disease stage. Furthermore, orthotopic transplantation of these organoids fully recapitulates the disease spectrum. In addition to more closely resembling the native environment of the cells, a distinct advantage of organoids over 2D culture methods is the ability to retain more heterogeneity under these conditions due to the minimal selective pressure. It is also possible that this system may also more readily support growth of stroma to more closely recapitulate the native environment. Finally, a key advantage is that organoids can be prepared from tissue biopsies with relative ease and within a short time frame, such that therapeutic testing can be evaluated on organoids in parallel with the patient's treatment. These properties suggest that there is significant application for personalized medicine. Thus, it remains to be determined how predictive organoids are for therapeutic responses.

Conclusion

Models of iCCA have progressed significantly over the past decade. Recent genomic advancements have enabled genetic characterization of hepatic malignancies and have fueled the rapid development of sophisticated animal models, from conditional GEMMs to refined somatic gene-editing tools. These advanced systems will enable a more thorough

understanding of the development and progression of the disease and will provide flexible platforms for the evaluation of new treatments in a precise manner.

Disclosure

The authors report no conflicts of interest in this work.

References

- Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nat Rev Gastroenterol Hepatol*. 2016;13(5):261–280.
- Liu Y, Meyer C, Xu C, et al. Animal models of chronic liver diseases. *Am J Physiol Gastrointest Liver Physiol*. 2013;304(5):G449–G468.
- De Minicis S, Kisseleva T, Francis H, et al. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. *Dig Liver Dis*. 2013;45(6):450–459.
- Nakagawa H, Hikiba Y, Hirata Y, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. *Proc Natl Acad Sci U S A*. 2014;111(3):1090–1095.
- Moriconi F, Ramadori P, Schultze FC, et al. Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development. *Histochem Cell Biol*. 2013;139(3):473–485.
- Heindryckx F, Bogaerts E, Coulon SH, et al. Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. *Eur J Gastroenterol Hepatol*. 2012;24(9):1020–1032.
- Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. *Gastroenterology*. 2011;141(1):378–88, 388.e1–4.
- Sudsarn P, Boonmars T, Ruangjirachuporn W, et al. Combination of praziquantel and aspirin minimizes liver pathology of hamster *Opisthorchis viverrini* infection associated cholangiocarcinoma. *Pathol Oncol Res*. 2016;22(1):57–65.
- Yothaisong S, Thane M, Namwat N, et al. *Opisthorchis viverrini* infection activates the PI3K/AKT/PTEN and Wnt/beta-catenin signaling pathways in a Cholangiocarcinogenesis model. *Asian Pac J Cancer Prev*. 2014;15(23):10463–10468.
- Wonkchalee N, Boonmars T, Laummaunwai P, et al. A combination of praziquantel and the traditional medicinal plant *Thunbergia laurifolia* on *Opisthorchis viverrini* infection and cholangiocarcinoma in a hamster model. *Parasitol Res*. 2013;112(12):4211–4219.
- Laothong U, Pinlaor P, Boonsiri P, et al. Melatonin inhibits cholangiocarcinoma and reduces liver injury in *Opisthorchis viverrini*-infected and N-nitrosodimethylamine-treated hamsters. *J Pineal Res*. 2013;55(3):257–266.
- Chusorn P, Namwat N, Loilome W, et al. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. *Tumour Biol*. 2013;34(3):1579–1588.
- Lee J-H, Rim H-J, Sell S. Heterogeneity of the “oval-cell” response in the hamster liver during cholangiocarcinogenesis following *Clonorchis sinensis* infection and dimethylnitrosamine treatment. *J Hepatol*. 1997;26(6):1313–1323.
- Mu X, Pradere J-P, Affò S, et al. Epithelial transforming growth factor- β signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma. *Gastroenterology*. 2016;150(3):720–733.
- Li J, Razumilava N, Gores GJ, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. *J Clin Invest*. 2014;124(7):3241–3251.
- Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. *J Clin Invest*. 2012;122(11):3914–3918.
- Guest RV, Boulter L, Kendall TJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. *Cancer Res*. 2014;74(4):1005–1010.
- Thamavit W, Bhamarapavati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in *Opisthorchis viverrini*-infected Syrian golden hamsters. *Cancer Res*. 1978;38(12):4634–4639.
- Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. *Cancer Res*. 2006;66(13):6622–6627.
- Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4a to block hepatocyte differentiation and promote biliary cancer. *Nature*. 2014;513(7516):110–114.
- Jörs S, Jeliazkova P, Ringelhan M, et al. Lineage fate of ductular reactions in liver injury and carcinogenesis. *J Clin Invest*. 2015;125(6):2445–2457.
- Zhu L, Finkelstein D, Gao C, et al. Multi-organ mapping of cancer risk. *Cell*. 2016;166(5):1132–1146.e7.
- Frese KK, Tuveson DA. Maximizing mouse cancer models. *Nat Rev Cancer*. 2007;7(9):645–658.
- Zhang J, Jiao J, Cermelli S, et al. miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells. *Cancer Res*. 2015;75(9):1859–1867.
- Galicia VA, He L, Dang H, et al. Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. *Gastroenterology*. 2010;139(6):2170–2182.
- Morris SM, Carter KT, Baek JY, et al. TGF-beta signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. *Oncogene*. 2015;34(25):3273–3282.
- Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. *J Clin Invest*. 2006;116(7):1843–1852.
- Chen WT, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS. GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. *Oncogene*. 2014;33(42):4997–5005.
- Chen WT, Tseng CC, Pfaffenbach K, et al. Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis. *Hepatology*. 2014;59(3):947–957.
- Zender S, Nickeleit I, Wuestefeld T, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. *Cancer Cell*. 2013;23(6):784–795.
- Nishio M, Sugimachi K, Goto H, et al. Dysregulated YAP1/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. *Proc Natl Acad Sci U S A*. 2016;113(1):E71–E80.
- El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. *PLoS One*. 2013;8(10):e77433.
- Morris SM, Baek JY, Koszarek A, Kannurn S, Knoblaugh SE, Grady WM. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. *Hepatology*. 2012;55(1):121–131.
- Terada M, Horisawa K, Miura S, et al. Kupffer cells induce Notch-mediated hepatocyte conversion in a common mouse model of intrahepatic cholangiocarcinoma. *Sci Rep*. 2016;6:34691.
- Marsh V, Davies EJ, Williams GT, Clarke AR. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. *J Pathol*. 2013;230(2):165–173.
- Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nat Genet*. 2001;29(4):418–425.

37. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev.* 2001;15(24):3243–3248.
38. Yanger K, Zong Y, Maggs LR, et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. *Genes Dev.* 2013;27(7):719–724.
39. Yanger K, Knigin D, Zong Y, et al. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. *Cell Stem Cell.* 2014;15(3):340–349.
40. Font-Burgada J, Shalapour S, Ramaswamy S, et al. Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. *Cell.* 2015;162(4):766–779.
41. Ikenoue T, Terakado Y, Nakagawa H, et al. A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. *Sci Rep.* 2016;6:23899.
42. Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. *Nat Rev Cancer.* 2015;15(11):653–667.
43. Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. *J Clin Invest.* 2012;122(8):2911–2915.
44. Chan-on W, Nairismägi M-L, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nat Genet.* 2013;45(12):1474–1478.
45. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. *Nat Genet.* 2015;47(9):1003–1010.
46. Tschaharganeh DF, Xue W, Calvisi DF, et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. *Cell.* 2014;158(3):579–592.
47. O'Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. *Cancer Res.* 2012;72(6):1557–1567.
48. Boulter L, Guest RV, Kendall TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. *J Clin Invest.* 2015;125(3):1269–1285.
49. Guest RV, Boulter L, Dwyer BJ, et al. Notch3 drives development and progression of cholangiocarcinoma. *Proc Natl Acad Sci U S A.* 2016;113(43):12250–12255.
50. Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. *Cancer Immunol Res.* 2015;3:399–411.
51. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. *Proc Natl Acad Sci U S A.* 2013;110(48):19513–19518.
52. Saborowski M, Saborowski A, Morris JP, et al. A modular and flexible ESC-based mouse model of pancreatic cancer. *Genes Dev.* 2014;28(1):85–97.
53. Ju HL, Han KH, Lee JD, Ro SW. Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy. *Int J Cancer.* 2016;138(7):1601–1608.
54. Ding N, Che L, Li XL, et al. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. *World J Gastroenterol.* 2016;22(6):2071–2080.
55. Che L, Fan B, Pilo MG, et al. Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. *Oncogenesis.* 2016;5(12):e274.
56. Ho C, Wang C, Mattu S, et al. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. *Hepatology.* 2012;55(3):833–845.
57. Huntzicker EG, Hotzel K, Choy L, et al. Differential effects of targeting Notch receptors in a mouse model of liver cancer. *Hepatology.* 2015;61(3):942–952.
58. Fan L, Xu C, Wang C, et al. Bmi1 is required for hepatic progenitor cell expansion and liver tumor development. *PLoS One.* 2012;7(9):e46472.
59. Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. *Hepatology.* 2015;61(5):1627–1642.
60. Li X, Tao J, Cigliano A, et al. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. *Oncotarget.* 2015;6(12):10102–10115.
61. Rizvi S, Yamada D, Hirsova P, et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. *J Biol Chem.* 2016;291(15):8031–8047.
62. O'Donnell KA, Keng VW, York B, et al. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Nco2/Src-2 in liver cancer. *Proc Natl Acad Sci U S A.* 2012;109(21):E1377–E1386.
63. Keng VW, Villanueva A, Chiang DY, et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. *Nat Biotechnol.* 2009;27(3):264–274.
64. Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. *Nat Rev Cancer.* 2015;15(7):387–395.
65. Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. *Nature.* 2014;514(7522):380–384.
66. Weber J, Ollinger R, Friedrich M, et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. *Proc Natl Acad Sci U S A.* 2015;112(45):13982–13987.
67. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nat Biotechnol.* 2014;32(6):551–553.
68. Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. *Nat Rev Cancer.* 2015;15(5):311–316.
69. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discov.* 2014;4(9):998–1013.
70. Fichtner I, Slisow W, Gill J, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. *Eur J Cancer.* 2004;40(2):298–307.
71. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. *Clin Cancer Res.* 2008;14(20):6456–6468.
72. Nemati F, Bras-Goncalves R, Fontaine JJ, et al. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. *Anticancer Drugs.* 2009;20(10):932–940.
73. Cavalloni G, Peraldo-Neia C, Sassi F, et al. Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. *BMC Cancer.* 2016;16:90.
74. Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. *Cancer Discov.* 2016;6(7):727–739.
75. Baker LA, Tiriack H, Clevers H, Tuveson DA. Modeling pancreatic cancer with organoids. *Trends Cancer.* 2016;2(4):176–190.
76. Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. *Cell.* 2015;160(1–2):324–338.
77. Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. *Nat Med.* 2015;21(11):1364–1371.

Gastrointestinal Cancer: Targets and Therapy

Dovepress

Publish your work in this journal

Gastrointestinal Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on gastro-intestinal cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the

cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/gastro-intestinal-cancer-targets-and-therapy-journal>